Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

Kush Dalal; Mani Roshan-Moniri; Aishwariya Sharma; Huifang Li; Fuqiang Ban; Mohamed Hessein; Michael Hsing; Kriti Singh; Eric LeBlanc; Scott Dehm; Emma S. Tomlinson Guns; Artem Cherkasov; Paul S. Rennie

doi:10.1074/jbc.M114.553818

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

Kush Dalal
, Mani Roshan-Moniri
, Aishwariya Sharma
, Huifang Li
, Fuqiang Ban
, Mohamed Hessein
, Michael Hsing
, Kriti Singh
, Eric LeBlanc
, Scott Dehm
, Emma S. Tomlinson Guns
, Artem Cherkasov
, Paul S. Rennie

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Background: The androgen receptor (AR) is a transcription factor regulating progression of prostate cancer.

Results: Developed compounds inhibit AR transcriptional activity in vitro and in vivo by selective targeting of the AR-DNA-binding domain (DBD).

Conclusion: By targeting the DBD, the compounds differ from conventional anti-androgens.

Significance: Anti-androgens with a novel mechanism of action have the potential to treat recurrent prostate cancer.

Original language	English (US)
Pages (from-to)	26417-26429
Number of pages	13
Journal	Journal of Biological Chemistry
Volume	289
Issue number	38
DOIs	https://doi.org/10.1074/jbc.M114.553818
State	Published - Sep 19 2014

Bibliographical note

Publisher Copyright:
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1074/jbc.M114.553818

Find It

Find It at U of M Libraries

Cite this

Dalal, K., Roshan-Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., LeBlanc, E., Dehm, S., Tomlinson Guns, E. S., Cherkasov, A., & Rennie, P. S. (2014). Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. Journal of Biological Chemistry, 289(38), 26417-26429. https://doi.org/10.1074/jbc.M114.553818

Dalal, K, Roshan-Moniri, M, Sharma, A, Li, H, Ban, F, Hessein, M, Hsing, M, Singh, K, LeBlanc, E, Dehm, S, Tomlinson Guns, ES, Cherkasov, A & Rennie, PS 2014, 'Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer', Journal of Biological Chemistry, vol. 289, no. 38, pp. 26417-26429. https://doi.org/10.1074/jbc.M114.553818

@article{74dc0420fbd9478bb175faf707efd7d7,

title = "Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer",

abstract = "Background: The androgen receptor (AR) is a transcription factor regulating progression of prostate cancer.Results: Developed compounds inhibit AR transcriptional activity in vitro and in vivo by selective targeting of the AR-DNA-binding domain (DBD).Conclusion: By targeting the DBD, the compounds differ from conventional anti-androgens.Significance: Anti-androgens with a novel mechanism of action have the potential to treat recurrent prostate cancer.",

author = "Kush Dalal and Mani Roshan-Moniri and Aishwariya Sharma and Huifang Li and Fuqiang Ban and Mohamed Hessein and Michael Hsing and Kriti Singh and Eric LeBlanc and Scott Dehm and \{Tomlinson Guns\}, \{Emma S.\} and Artem Cherkasov and Rennie, \{Paul S.\}",

note = "Publisher Copyright: {\textcopyright} 2014 by The American Society for Biochemistry and Molecular Biology, Inc.",

year = "2014",

month = sep,

day = "19",

doi = "10.1074/jbc.M114.553818",

language = "English (US)",

volume = "289",

pages = "26417--26429",

journal = "Journal of Biological Chemistry",

issn = "0021-9258",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "38",

}

TY - JOUR

T1 - Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

AU - Dalal, Kush

AU - Roshan-Moniri, Mani

AU - Sharma, Aishwariya

AU - Li, Huifang

AU - Ban, Fuqiang

AU - Hessein, Mohamed

AU - Hsing, Michael

AU - Singh, Kriti

AU - LeBlanc, Eric

AU - Dehm, Scott

AU - Tomlinson Guns, Emma S.

AU - Cherkasov, Artem

AU - Rennie, Paul S.

PY - 2014/9/19

Y1 - 2014/9/19

N2 - Background: The androgen receptor (AR) is a transcription factor regulating progression of prostate cancer.Results: Developed compounds inhibit AR transcriptional activity in vitro and in vivo by selective targeting of the AR-DNA-binding domain (DBD).Conclusion: By targeting the DBD, the compounds differ from conventional anti-androgens.Significance: Anti-androgens with a novel mechanism of action have the potential to treat recurrent prostate cancer.

AB - Background: The androgen receptor (AR) is a transcription factor regulating progression of prostate cancer.Results: Developed compounds inhibit AR transcriptional activity in vitro and in vivo by selective targeting of the AR-DNA-binding domain (DBD).Conclusion: By targeting the DBD, the compounds differ from conventional anti-androgens.Significance: Anti-androgens with a novel mechanism of action have the potential to treat recurrent prostate cancer.

UR - https://www.scopus.com/pages/publications/84907222763

UR - https://www.scopus.com/pages/publications/84907222763#tab=citedBy

U2 - 10.1074/jbc.M114.553818

DO - 10.1074/jbc.M114.553818

M3 - Article

C2 - 25086042

AN - SCOPUS:84907222763

SN - 0021-9258

VL - 289

SP - 26417

EP - 26429

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

IS - 38

ER -

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this